Absci 为 AI 设计的抗 PRLR 抗体 ABS-201 开设女性专属队列,用于模式性脱发的 Phase 1/2a 临床试验。该抗体有望带来近三十年来雄激素性脱发的首个新作用机制,Absci 近期已公布 HEADLINE 试验 Phase 1 积极中期数据。模式性脱发影响数百万女性,但治疗选择仍有限。
Our ABS-201 program for pattern hair loss was recently featured in Bustle, covering the opening of a dedicated women’s cohort in our Phase 1/2a clinical trial. Pattern hair loss affects millions of women, yet treatment options remain limited. Absci is working to rapidly advance ABS-201, our AI-designed anti-PRLR antibody, which has the potential to introduce the first new mechanism of action for androgenetic alopecia in nearly three decades. We recently released positive interim Phase 1 data from the HEADLINE trial.
Read the article: https://www.bustle.com/wellness/early-stage-hair-loss-trial-opens-a-cohort-just-for-women
🦲Learn more about HEADLINE: https://headlinetrial.com/
来源:Absci · x.com